Diabetic cystopathy


Cite item

Full Text

Abstract

About the authors

L M Gorilovsky

D A Lakhno

References

  1. Mastri A. R. Neuropathology of diabetic neurogenic bladder. Ann. Intern. Med. 1980; 92 (2, pt 2): 316-318.
  2. Yerkes A. M. Urinary incontinence in individuals with diabetes mellitus. Diabetes Spectrum 1998; 11 (4): 241-247.
  3. Longhurst P. A., Belis J. A. Abnormalities of rat bladder contractility in streptozotocin-induced diabetes mellitus. J Pharmacol. Exp. Ther. 1986; 238 (3): 773-777.
  4. Venkateswarlu Karicheti, Christ G. J. Reduced response to katp channel openers in stz-diabetic rat detrusor smooth muscle: a possible role in overactivity. Орландо 2002. Program abstracts. J. Urol. (Baltimore) 2002; 167 (suppl. 4): 40.
  5. Бачурин В. И. Особенности, течение, лечение инфекций почек и мочевыводяших путей у больных сахарным диабетом. В кн.: Третья Днепропетровская обл. науч.-практ. конф. по сепсисологии и актуальным вопросам урологии. Депропетровск; 1981. 112, 114.
  6. Бачурин В. И. Динамика показателей гомеостаза и их коррекция в процессе оперативного лечения мочекаменной болезни и аденомы предстательной железы у больных сахарным диабетом: Автореф. дис. ... д-ра мед. наук. Киев1984.
  7. Ковальчук И. А., Симоненко А. А., Иткис В. Г., Пецкар А. Г. Особенности лечения больных с воспалительными заболеваниями органов мочеполовой системы на фоне сахарного диабета. В кн.: Актуальные вопросы урологии. Тезисы докладов. Львов; 1983. 13-14.
  8. Маковский В. Г. Неотложное оперативное лечение больных с сахарным диабетом и заболеваниями мочеполовых органов. В кн.: Тезисы науч. работ 3-го Съезда урологов УССР. Днепропетровск; 1980. 110-111.
  9. Ширшова Ю. Н. К вопросу о сахарном диабете у урологических больных. В кн.: Материалы 3-й науч. конф. клиники Московского мед. ин-та и клинической больницы № 50. М.; 1970. 244-246.
  10. Ширшова Ю. Н. Лечение урологических больных, страдающих сахарным диабетом: Автореф. дис. ... канд. мед. наук. М.; 1972.
  11. Рабиа А. X. Особенности клиники, течения и лечения некоторых заболеваний мочеполовой системы при сахарном диабете: Автореф. дис. ... канд. мед. наук. М.; 1970.
  12. Гориловский Л. М., Вязенкин С. М., Рабиа А. Аденомэктомия при сахарном диабете. Сов. мед. 1977; 9: 65-69.
  13. Борисов В. В., Демина Т. Л., Станкович Е. Ю. Диагностика и симптоматическое лечение гиперрефлексии мочевого пузыря у больных рассеянным склерозом. В кн.: Сборник материалов X Конференции "Нейроиммунология". М.; 2000. 144-145.
  14. Мазо Е. Б., Чепуров А. К., Кривобородов Г. Г., Зайцев Н. В. Временные уретральные стенты у больных с нейрогенной дисфункцией мочевого пузыря. Урология 2002; 1: 42-45.
  15. Саламов А. К. Лечение доброкачественной гиперплазии предстательной железы у больных сахарным диабетом: Автореф. дис. ... канд. мед. наук. Харьков; 1995.
  16. Frimodt-Moller С. Diabetic cystopathy: epidemiology and related disorders. Ann. Intern. Med. 1980; 92 (2, pt 2): 318-321.
  17. Frimodt-Moller С. Diabetic cystopathy. I: A clinical study of the frequency of bladder dysfunction in diabetics. Dan. Med. Bull. 1976; 23: 267-278.
  18. Nijhawan S., Mathur A., Singh V. Bhandari V. M. Autonomic and peripheral neuropathy in insulin dependent diabetics. J. Assoc. Physicians India 1993; 41 (9): 565-566.
  19. Olapade-Olaopa E. O., Morley R. N., Carter С. J., Walmsley В. Н. Diabetic cystopathy presenting as primary acute urinary retention in a previously undiagnosed young male diabetic patient. J. Diabet. Complicat. 1997; 11 (6): 350-351.
  20. Katsumi Sasaki, Naoki Yoshimura, Michael B. Chancellor. Implications of diabetes mellitus in urology. Urol. Clin. N. Am. 2003; 30 (1).
  21. Buck A. C., Reed P. I., Siddig Y. K. et al. Bladder dysfunction and neuropathy in diabetes. Diabetologia 1976; 12 (3): 251 - 258.
  22. Faerman L, Maler M., Jadzinsky M. et al. Asymptomatic neurogenic bladder in juvenile diabetes. Ibid. 1971; 7(3): 168-172.
  23. Veda Т., Yoshimura N., Yoshida O. Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J. Urol. (Baltimore) 1997; 157 (2): 580-584.
  24. Katsumi Т., Murayama К. A clinical study on the R-R interval of ECG in diabetic neurogenic bladder. Hinyokika Kiyo 1986; 32 (6): 819-822.
  25. Norden G., Granerus G., Nyberg G. Diabetic cystopathy - a risk factor in diabetic nephropathy? J. Diabet. Complicat. 1988; 2 (4): 203-206.
  26. Torffvit O., Agardh С. D., Mattiasson A. Lack of association between cystopathy and progression of diabetic nephropathy in insulin-dependent diabetes mellitus. Scand. J. Urol. Nephrol 1997; 31 (4): 365-369.
  27. Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. Ann. Intern. Med. 1980; 92 (2): 321-323.
  28. Ali S. T. Measurement of the residual urine index in insulin-dependent and non-insulin dependent diabetic men with and without neuropathy. Acta Physiol. Hung. 1997-1998; 85 (3V 243-250.
  29. Kaplan S. A., Blaivas J. G. Diabetic cystopathy. J. Diabet. Complicat. 1988; 2 (3): 133-139.
  30. Watanabe Т., Miyagawa I. Characteristics of detrusor contractility during micturition in diabetics. Neurourol. and Urodyn. 1999; 18 (3): 163-171.
  31. Michel M. C., Mehlburger L., Schumacher H. et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J. Urol. (Baltimore) 2000; 163: 1725- 1729.
  32. Agency for Health Care Policy and Research: Urinary incontinence in adults: acute and chronic management. Clinical practice guideline. Washington, D. C, U. S. Public Health Service, Department of Health and Human Services; 1996; vol. 7: 19- 71.
  33. Abramson A. Neurogenic bladder: a guide to evaluation and management. Arch. Phys. Med. Rehabil. 1983; 64: 6-10.
  34. Ishigooka M., Suzuki Y., Hayami S. et al. Role of symptom scoring and uroflowmetry in patients with diabetic cystopathy. Int. Urol. Nephrol. 1996; 28 (6): 761-766.
  35. Frimodt-Moller C. Diabetic cystopathy: a review of the urodynamic and clinical features of neurogenic bladder dysfunction in diabetes mellitus. Dan. Med. Bull. 1978; 25 (2): 49-60.
  36. Bravas J. G. Neurogenic dysfunction. In: Yalla S. U., McGuirc E. J., Elbadawi A., eds. Neurourology and urodynamics: principles and practice. New York: Macmillan Publishing Company; 1988. 347-350.
  37. Kaplan S. А., Те А. Е., Blaivas J. G. Urodynamic findings in patients with diabetic cystopathy. J. Urol. (Baltimore) 1995; 153 (2): 342-344.
  38. Stater P., Libow L. Cystometric evaluation of bladder dysfunction in elderly diabetic patients. Arch. Intern. Med. 1990; 150 (4): 810-813.
  39. Kutami К. Vesicourethral dysfunction of diabetic patients. Nippon Hinyokika Gakkai Zasshi 1991; 82 (7): 1074-1083.
  40. Kang Y. M., Littlejohn J. O., Ghafar M., Kaplan S. A. Urodynamic findings in patients with DM and BPH. American Urological Association. Annual meeting, Orlando 2002. Program abstracts. J. Urol. (Baltimore) 2002; 67 (suppl. 4): 270.
  41. Prantil R. L., Jankowski R. J., Torimoto K. et al. Dramatic effects of diabetes mellitus on urethral biomechanics: implications for diabetic cystopathy. Ibid. 248.
  42. Torimolo K., Yoshiyama M., Vorp D. A. et al. Dramatic effects of diabetes mellitus on in vivo urethral function: implications for understanding the pathogenesis of diabetic cystopathy. Ibid. 248.
  43. Van Poppel H., Baert L., Stessens R. et al. Histochemical assessment of the intrinsic innervation of the normal urinary bladder. Urol. Int. 1988; 43 (3): 145-148.
  44. Van Poppel H., Stessens R., Van Damme B. et al. Diabetic cystopathy: neuropathological examination of urinary bladder biopsies. Eur. Urol. 1988; 15 (1-2): 128-131.
  45. Van Poppel H., Stessens R., Baert L. et al. Endoscopic biopsies for quantitative nerve density evaluation of the urinary bladder. Ibid. 14 (3): 236-239.
  46. Van Poppel H., Stessens R., Baert L. et al. Innervation density in the stroma and the muscular tunica in biopsies of the normal and pathologic bladder. Ann. Urol. (Paris) 1989; 23 (5): 398401.
  47. Parsons К. F., Scott A. G., Traer S. Endoscopic biopsy in the diagnosis of peripheral denervation of the bladder. Br. J. Urol. 1980; 52 (6): 455-459.
  48. Paro M., Italiano G., Travagli R. A. et al. Cystometric changes in alloxan diabetic rats: evidence for functional and structural correlates of diabetic autonomic neuropathy. J. Auton. Nerv. Syst. 1990; 30 (1): 1-11.
  49. Bradley W. E. Diagnosis of urinary bladder dysfunction in diabetes mellitus. Ann. Intern. Med. 1980; 92 (2, pt 2): 323-326.
  50. Frimodt-Moller C., Mortensen S. Treatment of diabetic cystopathy. Ibid. 327-328.
  51. Tong Y. C., Chin W. Т., Cheng J. T. Alterations in urinary bladder M2-muscarinic receptor protein and mRNA in 2-week streptozotocin-induced diabetic rats. Neurosci. Lett. 1999' 277 (3): 173-176.
  52. Nobutaka khiyanagi; Toshihiko Tsujii; Hitoshi Masuda et al. Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction. J. Urol. (Baltimore) 2002; 168: 303-307.
  53. Балаболкин М. И. Диабетология. М.: Медицина; 2000.
  54. Рунов Г. П., Занозина О. В. Диабетическая полинейропатия: информ. письмо. Н. Новгород; 1996.
  55. Low P. A., Nickander К. К., Tntschler Н. J. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997; 46 (suppl. 2): 38-42.
  56. Аметов А. С., Строков И. А. Диабетическая полинейропатия: настоящее и будущее. Рос. мед. вести 2001; 4 (IV 35- 40.
  57. Sies В., ed. Oxidative stress oxidants and antioxidants. London: Academic Press; 1991.
  58. Kihara M., Low P. A. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp. Neurol. 1995- 132' 180-185.
  59. Bierhaus A., Chevion S., Chevion M. et al. Advanced glycation end productinduced activation of NF-kB is suppressed by alipoic acid in cultured endothelial cells. Diabetes 1997- 461481-1490.
  60. Changolkar A., Hypolite J., Wein A. J., Chacko S. Decreased contractility of the detrusor smooth muscle in diabetes is associated with alteration of the intracellular reduction-oxidation(redox) state and activation of nuclear transcription factor kappa В (NF-KB). American Urological Association. Annual meeting, Orlando 2002. Program abstracts. J. Urol. (Baltimore) 2002; 167 (suppl. 4): 248.
  61. Tong Y. C., Chin W. Т., Cheng J. T. Role of sorbitol in the tipregulation of urinary bladder M (2) muscarinic receptors in streptozotocin-induced diabetic rats. Neurourol. and Urodyn 2002; 21 (2): 154-159.
  62. Котов С. В., Калинин А. П., Рудакова И. Г. Диабетическая нейропатия. М.: Медицина; 2000.
  63. Mumtaz F. H., Sullivan M. E., Thompson С. S. et al. Alterations in the nitric oxide synthase binding sites and non-adrenergic, non-cholinergic mediated smooth muscle relaxation in the diabetic rabbit bladder outlet: possible relevance to the pathogenesis of diabetic cystopathy. J. Urol. (Baltimore) 1999; 162: 558.
  64. Scarpini E., Bianchi R., Moggio M. et al. Decrease of nerve Na+, K(+)-ATPase activity in the pathogenesis of human diabetic neuropathy. J. Neurol. Sci. 1993; 120 (2): 159-167.
  65. Hellweg R. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J. Neurosci. Res. 1990; 26 (2): 258-267.
  66. Katsumi Sasaki, Chancellor M. В., Phelan M. W. et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia. J. Urol. (Baltimore) 2002; 168 (3): 1259-1264.
  67. Sasaki K., Yoshimura N., Phelan M. W. et al. Nerve growth factor (NGF) gene therapy mediated by herpes simplex virus (HSV) vectors reverses bladder dysfunction and the decline in NGF expression in L6-SI afferent neurons in diabetic rats. Ibid. 2001; 165 (suppl.): 274A.
  68. Mumtaz F. H., Dashwood M. R., Thompson C. S. et al. Increased expression of endothelin В receptors in the diabetic rabbit urinary bladder: functional relevance. Br. J. Urol. Int 1999; 83 (1): 113-122.
  69. Mumtaz F. H., Shukla N., Sullivan M. E. et al. Inhibition of diabetic bladder smooth muscle cell proliferation by endothelin receptor antagonists. Urol. Res. 2000; 28 (4): 254-259.
  70. Frimodt-Moller C., Mortensen S. Treatment of diabetic cystopathy. Ann. Intern. Med. 1980; 92 (2, pt 2): 327-328.
  71. Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy. Curr. Diabet. Rep. 2001; 1: 216-227.
  72. DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann. Intern Med. 1995; 122 (8): 561-568.
  73. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
  74. Ziegler D. Clinical aspects, diagnosis and therapy of diabetic neuropathy. Ther. Umsch. 1996; 53 (12): 948-957.
  75. Gentile S., Bronzino P., Persico M. et al. Diabetic neuropathy. Ill: Autonomic neuropathy. Genitourinary system. Minerva Med. 1984; 75 (17): 967-974.
  76. Ay an S., Kaloglu C., Gokce G. et al. Effect of insulin therapy for diabetic cystopathy-urodynamic and histological findings in a rabbit model. Scand. i. Urol. Nephrol. 1999; 33 (6): 392-395.
  77. Rodgers J. M. et al. Glibenclamide enhances stretch-activated contraction in rat bladders and shows protective effects in human diabetic cystopathy. American Urological Association. Annual meeting, Orlando 2002. Program abstracts. J. Urol. (Baltimore) 2002; 167 (suppl. 4): 42.
  78. Nagamatsu M., Nickander K. K., Schmelzer J. D. et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-1167.
  79. Строков И. А., Манухина Е. Б., Бахтина Л. Ю. и др. Состояние эндогенных протекторных систем у больных инсулинзависимым сахарным диабетом с полиневропатией - эффект антиоксидантной терапии. Бюл. экспер. биол. 2000; 10: 437-442.
  80. Галстян Г. Р., Анциферов М. Б. Лечение дистальной диабетической полинейропатии. Рус. мед. журн. 2000; 8 (4): 21 - 24.
  81. Кучмеровская Т. М., Пархомец П. К., Донченко Г. В. и др. Коррекция диабетических нейропатий с помощью ингибиторов альдозоредуктазы и пикамилона. Вопр. мед. химии 1999; 44 (6): 34-36.
  82. Hammarsten J., Hogstedt В., Holthuis N., Mellstrom D. Components of the metabolic syndrome. Risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Diseases 1998; 157-162.
  83. Hammarsten J., Hogstedt B. Clinical, anthropo-metric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999; 8: 29-36.
  84. Hammarsten J., Hogstedt B. Hyperinsulmaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 2001; 39 (2): 151-158.
  85. Chandler P. Т., Rege P. R., Knoblaugh R. A. Long-term application of intermittent urethral catheterization to the neurogenic bladder of diabetes mellitus. Acta Diabetol. Lat. 1978; 15 (1 - 2): 105-108.
  86. Lin D. W., Kuhr Ch. S., Marsh Ch. L., Novick A. С. Endoscopic treatment of bladder outlet obstruction in men after pancreas transplantation. J. Urol. (Baltimore) 1999; 162: 335.
  87. Takeshi Watanabe, Ikuo Miyagawa. The effect of partial cystectomy on the residual urine of a large bladder demonstrated in diabetic rats. Ibid. 161: 1010.
  88. Sango K., Verdes J. M., Hikawa N. et al. Nerve growth factor (NGF) restores depletions of calcitonin gene-related peptide and substance P in sensory neurons from diabetic mice in vitro. J. Neurol. Sci. 1994; 126 (1): 1-5.
  89. Diemel L. Т., Brewster W. J., Fernyhough P. et al. Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brainderived neurotrophic factor. Brain Res. Mol. Brain Res. 1994; 21 (1-2): 171-175.
  90. Schmidt Y., linger J. W., Bartke I. et al. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db)mice. Exp. Neurol. 1995; 132(1): 16-23.
  91. Apfel S. C., Arezzo J. C., Brownlee M. et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994; 634 (1): 7-12.
  92. linger J. W., Klitzsch Т., Pera S. et al. Nerve growth factor (NGF) and diabetic neuropathy in the rat: morphological investigation of the sural nerve, dorsal root ganglion, and spinal cord. Exp. Neurol. 1998; 153: 23-34.
  93. Akkina S. K., Patterson С. L., Wright D. E. GDNF rescues nonpeptidergic unmyelinated primary afferents in streptozotocintreated diabetic mice. Ibid. 2001; 167 (1): 173-182.
  94. Pradat P. F., Kennel P., Naimi-Sadaoui S. et al. Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies. Hum. Gene Ther. 2001; 12 (18): 2237-2249.
  95. Ishii D. N., Lupien S. B. Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J. Neurosci. Res. 1995; 40 (1): 138-144.
  96. Zhuang H. X., Snyder С. К., Pu S. F. et al. Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Exp. Neurol. 1996; 140 (2): 198-205.
  97. Phelan M. W., Yoshimura N., Goins W. F. et al. Nerve growth factor (NGF) gene therapy improves rat diabetic cystopathy, but does not increase pain sensation. J. Urol. (Baltimore) 2000; 163 (suppl.): 245A.
  98. Sasaki K., Yoshimura N., Phelan M. W. et al. Nerve growth factor (NGF) gene therapy mediated by herpes simplex virus (HSV) vectors reverses bladder dysfunction and the decline in NGF expression in L6-SI afferent neurons in diabetic rats. Ibid. 2001; 165 (suppl.): 274A.
  99. Goins W. F, Yoshimura N., Phelan M. W. et al. Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. Ibid. (5): 1748-1754.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies